The debate over use of interleukin-6 inhibitors including tocilizumab (Actemra) and sarilumab (Kevzara) in COVID-19 patients is likely to continue, as one international randomized trial found no benefit among patients with severe disease, while another ...
from Google Alert - health https://ift.tt/3krk5hn
via IFTTT
0 comments:
Post a Comment